Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases

Future Cardiology

Volumn 5, Issue 5, 2009, Pages 479-493

  Sakariassen, Kjell S ^a   Alberts, Peteris ^b   Fontana, Pierre ^c   Mann, Jessica ^d   Bounameaux, Henri ^c   Sorensen, Alexandra Santana ^b  

^a KellSa sas   (Italy)

^b EVOLVA SA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Cardiovascular Development Consulting GmbH   (Switzerland)

Author keywords

Arterial thrombosis; Arteriosclerosis; Renal proteinuria; Thromboxane receptor antagonists; Thromboxane synthase inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; APD 791; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1; DIPYRIDAMOLE; ELINOGREL; EPTIFIBATIDE; IBUPROFEN; ISOPROSTANE DERIVATIVE; NORPHENAZONE; OZAGREL; PAROGRELI; PHOSPHOLIPASE A2; PICOTAMIDE; PLACEBO; PRASUGREL; RAMATROBAN; SERATRODAST; TERUTROBAN; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 SYNTHASE; THROMBOXANE SYNTHASE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; THROMBIN RECEPTOR; THROMBOXANE A2;

ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE RESISTANCE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; HUMAN; KIDNEY DISEASE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK REDUCTION; STENT; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG EFFECTS; ENZYMOLOGY; KIDNEY DISEASES; METABOLISM;

ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; HUMANS; KIDNEY DISEASES; PLATELET AGGREGATION INHIBITORS; PROTEINURIA; RECEPTORS, THROMBIN; THROMBOSIS; THROMBOXANE A2; THROMBOXANE-A SYNTHASE; TICLOPIDINE;

EID: 70349204630     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.33     Document Type: Review

References (129)

1. Antithrombotic Trialist Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
2. Craven L: Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann. West Med. Surg. 4(2), 95 (1950).
3. Fontana P, Reny JL: New antiplatelet strategies in atherothrombosis and their indications. Eur. J. Vasc. Endovasc. Sur. 34(1), 10-17 (2007).
4. 2 receptor antagonist with with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemost. 71(1), 103-104 (1994).
5. Weiss HJ, Aledort LM: Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 2(7514), 495-497 (1967).
6. 2 receptor in vivo. Circulation 101(24), 2833-2840 (2000).
7. Montuschi P, Barnes P, Roberts LJ: Insights into oxidative stress: the isoprostanes. Curr. Med. Chem. 14(6), 703-717 (2007).
8. Pratico D, Lawson JA, Rokach J, FitzGerald GA: The isoprostanes in biology and medicine. Trends Endocrinol. Metab. 12(6), 243-247 (2001).
9. Samuelsson B: Arachidonic acid metabolism: role in inflammation. Z. Rheumatol. 50(Suppl. 1), 3-6 (1991).
10. Patrono C: Aspirin as an antiplatelet drug. N. Engl. J. Med. 330(18), 1287-1294 (1994).
11. Hankey GJ, Eikelboom JW: Antiplatelet drugs. Med. J. Aust. 178(11), 568-574 (2003).
12. Cayatte AJ, Du Y, Oliver-Krasinski J et al.: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in ApoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20(7), 1724-1728 (2000).
13. Cocozza M, Picano T, Oliviero U et al.: Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 26(4), 597-601 (1995).
14. Viles-Gonzalez JF, Fuster V, Corti R et al.: Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition - a magnetic resonance imaging study. Eur. Heart J. 26(15), 1557-1561 (2005).
15. Coleman RA: Prostanoid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. Godfraid T, Vanhoutte PM, Ruttolo RR, Humphrey PA (Eds). IUPHAR Media, London, UK, 227-244 (1998)
16. 2 receptors. J. Pharmacol. Exp. Ther. 270(2), 446-452 (1994).
17. 2 receptors. Cell Signal. 16(5), 521-533 (2004).
18. 2 receptor: cDNA cloning, expression and northern blot analysis. Biochem. Biophys. Res. Commun. 184(3), 1197-1203 (1992).
19. 2. J. Biol. Chem. 276(41), 37839-37845 (2001).
20. Habib A, FitzGerald GA, Maclouf J: Phosphorylation of the thromboxane receptor α, the predominant isoform expressed in human platelets. J. Biol. Chem. 274(5), 2645-2651 (1999).
21. Errasti AE, Luciani LI, Cesio CE et al.: Potentiation of adrenaline vasoconstrictor response by sub-threshold concentrations of U-46619 in human umbilical vein: involvement of smooth muscle prostanoid TPα receptor isoform. Eur. J. Pharmacol. 562(3), 227-235 (2007).
22. Qiao N, Reynaud D, Demin P, Halushka PV, Pace-Asciak CR: The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells. J. Pharmacol. Exp. Ther. 307(3), 1142-1147 (2003).
23. Berkes EA, Croker BP, Barri YM et al.: Thromboxane synthase expression co-localizes with infiltrating macrophages in renal allograft biopsies. Kidney Int. 48(4), 1344-1346 (1995).
24. 2, and prostacyclin. Pharmacol. Rev. 30(3), 293-331 (1978).
25. Takahashi N, Takeuchi K, Abe T, Sugawara A, Abe K: Immunolocalization of rat thromboxane receptor in the kidney. Endocrinology 137(11), 5170-5173 (1996).
26. Francois H, Athirakul K, Mao L, Rockman H. Coffman TM: Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 43 (Part 2), 364-369 (2004).
27. Francois H, Makhanova N, Ruiz P et al.: A role for the thromboxane receptor in L-NAME hypertension. Am. J. Physiol. Renal Physiol. 295(6), F1096-F1102 (2008).
28. 2 release by colorectal mucosa in inflammatory bowel disease. Aliment. Pharmacol. Ther. 10(3), 315-320 (1996).
29. Dogne JM, Hanson J, de Leval, X et al.: From the design to the clinical application of thromboxane modulators. Curr. Pharm. Des. 12(8), 903-923 (2006).
30. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41, 661-690 (2001).
31. ++ influx in human platelets. Thromb. Haemost. 59(1), 86-92 (1988).
32. Gresele P, Deckmyn H, Huybrechts E, Vermylen J: Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem. Pharmacol. 33(13), 2083-2088 (1984).
33. 2 activate the same receptor isoforms in human platelets. Thromb. Haemost. 87(1), 114-121 (2002).
34. Mezzetti A, Cipollone F, Cuccurullo, F: Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc. Res. 47(3), 475-488 (2000).
35. 2 receptor density and aggregation responses. Circulation 91(11), 2742-2747 (1995).
36. 2 receptor gene in healthy volunteers. Thromb. Haemost. 96(3), 356-360 (2006).
37. 2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 94(4), 1662-1667 (1994).
38. 2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur. Heart J. 25(20), 1845-1852 (2004).
39. Bhagwat, SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA: Synthesis and structure of the platelet aggregation factor thrombozane A2. Nature 315 (6019), 511-513 (1985).
40. Gaussem P, Reny JL, Thalamas C et al.: The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost. 3(7), 1437-1445 (2005).
41. 2 receptor. J. Biol. Chem. 270(12), 7011 (1995).
42. 2 receptor. J. Biol. Chem. 269(30), 19256-19261 (1994).
43. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96(7), 2280-2286 (1997).
44. Sakariassen KS: Thrombus formation and hyperplasia triggered by vascular stents implanted in man. International Rev. Thromb. 3(2), 29-38 (2008).
45. Holme PA, Ørvim U, Hamers MJ et al.: Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler. Thromb. Vasc. Biol. 17(4), 646-653 (1997).
46. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
47. Ashton AW, Ware JA: Thromboxane A, receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ. Res. 95(4), 372-379 (2004).
48. 2 Circ. Res. 87(9), 739-745 (2000).
49. Sebekova K, Eifert T, Klassen A, Heidland A, Amann K: Renal effects of S18886 (Terutroban®), a TP receptor antagonist, in an experimental model of Type 2 diabetes. Diabetes 56(4), 968-974 (2007).
50. 2 in adults with minimal-change nephrotic syndrome. Clin. Nephrol. 53(1), 75-76 (2000).
51. 2 receptors: characterization and effect of adriamycin-induced nephrotic syndrome. Biochim. Biophys. Acta 1181(2), 148-154 (1993).
52. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
53. Pozzi C, Del VL, Casartelli D et al.: ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study. J. Nephrol. 19(4), 508-514 (2006).
54. Badr KF, Abi-Antoun TE: Isoprostanes and the kidney. Antioxid. Redox. Signal. 7(1-2), 236-243 (2005).
55. Nasrallah R, Clark J, Herbert RL: Prostaglandins in the kidney: developments since Y2K. Clin. Sci. (London) 113(7), 297-311 (2007).
56. Xu S, Jiang B, Maitland KA et al.: The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55(1), 110-119 (2006).
57. Hull RP, Goldsmith DJ: Nephrotic syndrome in adults. BMJ 336(7654), 1185-1189 (2008).
58. Singhal R, Brimble KS: Thromboembolic complications in the nephratic syndrome: pathophysiology and clinical management. Thromb. Res. 118(3), 397-407 (2006).
59. Jackson CA, Greaves M, Patterson AD, Brown CB, Preston FE: Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br. J. Haematol. 52(1), 69-77 (1982).
60. Yoshida N, Aoki N: Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 52(5), 969-977 (1978).
61. Nakano M, Hidaka. T, Ogura R et al.: Increased platelet thromboxane synthesis in renal glomerular disease. Prostaglandins Leukot. Essent. Fatty Acids 31(3), 113-116 (1988).
62. Alessandrini P, Salvati P, Pugliese F, Ciabattoni G, Patrono C: Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv. Prostaglandin Thromboxane Leukot. Res. 21, 707-710 (1990).
63. 2 synthase. Jpn. J. Pharmacol. 73(1), 73-82 (1997).
64. Hora K, Oguchi H, Furukawa T, Hora K, Tokunaga S: Effects of a selective .. thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Nephron 56(3), 297-305 (1990).
65. 2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice. Jpn. J. Pharmacol. 63(4), 433-438 (1993).
66. Kawakage M, Sato K, Karasawa A: Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice. Jpn. J. Pharmacol. 65(2), 163-166 (1994).
67. Lariviere R, Moreau C, Rodrigue ME, Lebel M: Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins Leukot. Essent. Fatty Acids 71(2), 103-109 (2004).
68. Matsuo Y, Takagawa I, Koshida H et al.: Antiproteinurin effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 50(1), 1-8 (1995).
69. Sebekova K, Ramuscak A, Boor P, Heidland A, Amann K: The selective TP receptor antagonist, S18886 (Terutroban®) attenuates renal damage in the double transgenic rat model of hypertension. Am. J. Nephrol. 28(1), 47-53 (2008).
70. Spurney RF, Fan PY, Ruiz P et al.: Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int. 41(4), 973-982 (1992).
71. Barstad RM, Ørvim U, Hamers MJ et al.: Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb. Haemost. 75(5), 827-832 (1996).
72. Veen G, Meyer A, Verheugt FW et al.: Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. J. Am. Coll. Cardiol. 22(7), 1755-1762 (1993).
73. Roald HE, Barstad RM, Kierulf P et al.: Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human-blood independently of the blood flow conditions. Thromb. Haemost. 71(5), 655-662 (1994).
74. Roald HE, Ørvim U, Bakken IJ et al.: Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler. Thromb. 14(4), 617-621 (1994).
75. Sakariassen KS, Örning L, Stormorken H: Role ofADP and thromboxanes in human thrombus formation in ex vivo models. Platelets 8, 385-390 (1997).
76. Grove EL, Kristensen SD: Update on antiplatelet therapy: principles, problems and promises. Future Cardiol. 5(3), 247-258 (2009).
77. 2/ prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb. Haemost. 98(3), 662-669 (2007).
78. Hankey GJ, Eikelboom JW: Aspirin resistance. May be a cause of recurrent ischaemic vascular events in patients taking aspirin. BMJ 328(7438), 477-479 (2004).
79. Ferroni P, Basili S, Falco A, Davi G: Platelet activation in Type 2 diabetes mellitus. J. Thromb. Haemost. 2(8), 1282-1291 (2004).
80. Hovens MM, Snoep JD, Eikenboom JC et al.: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153(2), 175-181 (2007).
81. Snoep JD, Hovens MM, Eikenboom JC et al.: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154(2), 221-231 (2007).
82. Gori AM, Marcucci R, Migliorini A et al.: Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 52(9), 734-739 (2008).
83. Cattaneo M: Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J. Thromb. Haemost. 5(Suppl. 1), 230-237 (2007).
84. Frelinger AL, Li Y, Linden MD et al.: Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J. Thromb. Haemost. 6(12), 2035-2044 (2008).
85. Paul A, Calleja L, Camps J et al.: The continuous administration of aspirin attenuates atheroclerosis in apolipoprotein E-deficient mice. Life Sci. 68(4), 457-465 (2000).
86. Schulz C, Konrad I, Sauer S et al.: Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb. Haemost. 99(1), 190-195 (2008).
87. 2 receptor antagonist in human platelets. Thromb. Haemost. 61(3), 479-484 (1989).
88. Fitzgerald DJ, Fragetta J, FitzGerald GA: Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J. Clin. Invest. 82(5), 1708-1713 (1988).
89. Sun W, Gerhardinger C, Dagher Z, Hoehn T, Lorenzi M: Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 54(12), 3418-3426 (2005).
90. The DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38(4), 491-498 (1989).
91. De La CP, Arrebola M. Gonzalez-Correa A, Martinez-Cerdan E, Moreno A, de la Cuesta FS: Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats. Naunyn Schmiedebergs Arch. Pharmacol. 367(2), 204-210, (2003).
92. De La CP, Guerrero A, Paniego J, Arranz I, Moreno A, De La Cuesta FS: Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch. Pharmacol. 365(2), 96-101 (2002).
93. Grosser N, Schroder H: Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler. Thromb. Vasc. Biol. 23(8) 1345-1351 (2003).
94. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333(6174), 664-666 (1988).
95. Abele S, Wevand M, Wollin M et al.: Clopidogrel reduces the development of transplant arteriosclerosis. J. Thorac. Cardiovasc. Surg. 131(5), 1161-1166 (2006).
96. Chan A, Beach KW, Martin DC, Strandness DE Jr: Carotid artery disease in NIDDM diabetes. Diabetes Care 6(6), 562-569 (1983).
97. Jilma B, Fasching P, Ruthner C et al.: Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb. Haemost. 76(3), 328-332 (1996).
98. Tschoepe D. Roesen P, Kaufmann L et al.: Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur. J. Clin. Invest. 20(2), 166-170 (1990).
99. Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb. Res. 90(4), 181-190 (1998).
100. Davi G, Catalano I, Averna M et al.: Thromboxane biosynthesis and platelet function in Type II diabetes mellitus. N. Engl. J. Med. 322(25), 1769-1774 (1990).
101. Katoh K: Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 18(2), 89-98 (1992).
102. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8(1), 68-72 (1988).
103. Solomon SD, Lin J, Solomon CG et al.: Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116(23), 2687-2693 (2007).
104. Arnlov J, Evans JC, Meigs JB et al.: Low-grade albuminuria and incidence of cardiovascular disease events in northypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112(7), 969-975 (2005).
105. Lea J, Greene T., Hebert L et al.: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African-American study of kidney disease-and hypertension. Arch. Intern. Med. 165(8), 947-953 (2005).
106. de Zeeuw D, Remuzzi G, Parving HH et al.: Albuminuria, a therapeutic target for cardiovascular protection in Type 2 diabetic patients with nephropathy. Circulation 110(8), 921-927 (2004).
107. Remuzzi G, Imberti L, Rossini M et al.: Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J. Clin. Invest. 75(1), 94-101 (1985).
108. Coccheri S: Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67(7), 991-1026 (2007).
109. Giustina A, Bossoni S, Cittino A et al.: Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 42(1), 178-182 (1993).
110. Giustina A, Perini P, Desenzani P et al.: Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive Type 2 diabetic patients. Diabetes 47(3), 423-430 (1998).
111. Barnett AH, Wakelin K, Leatherdale BA et al.: Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet 1(8390), 1322-1325 (1984).
112. Niwa T, Maeda K, Shibata M, Yamada K: Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. Clin. Nephrol. 30(5), 276-281 (1988).
113. Tajiri Y, Inoguchi T, Umeda F, Nawata H: Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 10(3), 231-239 (1990).
114. Kontessis PS, Jones SL, Barrow SE et al.: Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. J. Lab Clin. Med. 121(3), 415-423 (1993).
115. A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report. J. Obstet. Gynaecol. 21(4), 357-365 (1995).
116. Samara EE: Seratrodast (AA-24 14) - a novel thromboxane-A, receptor antagonist. In: Cardiovascular Drug Reviews. Neva Press, Branford, CT, USA, 272-285 (1996).
117. Ogiso T, Iwaki M, Hara Y, Tanino T: Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations. J. Pharm. Sci. 86(10), 1111-1114 (1997).
118. Husted S: New developments, in oral antiplatelet therapy. In: European Heart Journal Supplements. D20-D27 (2007).
119. Alberts P. Fontana P, Sakariassen KS et al.: EV-077-3201-2TBS, a reversible dual thromboxane receptor antagonist and thromboxane synthase inhibitor, is more potent than aspirin in inhibiting arachidonic acid and collagen-induced human platelet aggregation in vitro. J. Thromb. Haemost. 7(Suppl. 2) Abstract PP-TH-103 (2009).
120. US Preventive Services Task Force: Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 150(6), 396-404 (2009).
121. Wolff T, Miller T, Ko S: Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 150(6), 405-410 (2009).
122. Bousser MG: Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc. Dis. 27(Suppl. 3), 12-19 (2009).
123. 3H) BAY U 3405 to washed human platelets and platelet membranes. Biochem. Pharmacol. 44(3), 495-503 (1992).
124. 2 receptor. Cardiovasc. Drug Rev. 22(2), 71-90 (2004).
125. van't Hof AW, Valgimigli M: Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs 69(1), 85-100 (2009).
126. Zeymer U, Wienbergen H: A review of clinical trials with eptifibatide in cardiology. Cardiovasc. Drug Rev. 25(4), 391-315 (2007).
127. Dindyal S, Kyriakides C: A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat. Cardiovasc. Drug Discov. 4(1), 6-14 (2009).
128. Hennerici MG, PERFORM Study Investigators: Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovasc. Dis. 27(Suppl. 3), 28-32 (2009).
129. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR: The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 48(12), 2539-2545 (2006).